Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 10/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | GRPR | P30550 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29871710 | 0.95 | CTSL (0.53) | GLP1RCXCR4IL23RCTSLCTSS | |
| SCHEMBL29484313 | 0.93 | NPBWR1 (0.55) | GLP1RCXCR4IL23RCTSLCTSS | |
| SCHEMBL30063985 | 0.91 | GLP1R (0.54) | GLP1RCXCR4IL23RCTSLCTSS | |
| SCHEMBL29670477 | 0.91 | NPBWR1 (0.56) | GLP1RCXCR4CTSLCTSSCTSK | |
| SCHEMBL30208638 | 0.91 | GLP1R (0.57) | GLP1RCXCR4IL23R | |
| SCHEMBL30952344 | 0.89 | GLP1R (0.61) | GLP1R | |
| SCHEMBL29484311 | 0.88 | GLP1R (0.56) | GLP1RIL23RCTSLCTSSCTSK | |
| SCHEMBL29613390 | 0.88 | IL23R (0.55) | GLP1RIL23RCTSLCTSSCTSK | |
| SCHEMBL29740501 | 0.88 | GLP1R (0.59) | GLP1RIL23R | |
| SCHEMBL30338573 | 0.88 | GLP1R (0.54) | GLP1RCXCR4IL23RCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | C9, C3AR1, SERPINC1 | GLP1R 1092/4885CXCR4 1600/4885IL23R 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.